April 16, 2025 Nvidia’s $5.5B AI Chip Crunch and ASML’s Tariff Jitters
Apple: Dividend Growth Ahead, But a Near-Term Slide Likely
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
Johnson & Johnson (JNJ) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: April 29, 2025 (19:55)
Sector: HealthcareThe share price of Johnson & Johnson (JNJ) now
News Impact Analyzer
Full report
This Week
|
Bullish | Impact: 5 | News: 3 (2/1/0) |
Previous Week
|
Bullish | Impact: 3 | News: 6 (3/2/1) |
Two Weeks Ago
|
Na | Impact: Na | News: Na |
Three Weeks Ago
|
Na | Impact: Na | News: Na |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Bullish | Opinions: 2 (1/1/0) |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: 1 |
Analyzing the Most Important JNJ news

Johnson & Johnson Unveils Promising Phase 2b Results for Innovative Bladder Cancer Treatment


Kenvue Gains as Dan Loeb’s Third Point Shows Interest


Halozyme Takes Legal Aim at Merck Over Keytruda Patent Clash

Historical and forecast chart of Johnson & Johnson stock
The chart below shows the historical price of Johnson & Johnson stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Johnson & Johnson stock price can be found in the table below.
Long-term forecasts by years.
Johnson & Johnson Analysts predictions review

Johnson & Johnson's stock outlook remains positive, supported by strong revenue growth in its pharmaceutical segment, which benefits from a diverse pipeline and high-performing key products. The company's recent spin-off of Kenvue has enhanced operational efficiency, focusing on higher-margin segments. JNJ’s medical devices and consumer health divisions provide balanced revenue diversification, despite moderate growth and inflationary pressures. Significant legal risks, particularly regarding talc litigation, remain a concern and could impact sentiment, though JNJ’s substantial cash reserves help mitigate this risk. Consistent dividend payments and strong free cash flow generation reinforce investor confidence, making the stock appealing for defensive and income-focused strategies.

Johnson & Johnson Defies Bearish Expectations With Resilient Growth Metrics

Johnson & Johnson's performance continues to demonstrate resilience, driven by its robust pharmaceutical division, which remains the cornerstone of its revenue growth. The company’s diverse pipeline and strong portfolio of immunology, oncology, and vaccine products safeguard its long-term competitive position despite sector-wide macro challenges, according to the author's analysis.
Expanding leadership in consumer health offers an additional layer of stability. The spin-off of Kenvue has not only streamlined operations but also highlighted JNJ's focus on higher-margin segments, which bodes well for its operational efficiency and profitability.
Focus on Legal Risks and Market Sentiment
Litigation overhangs surrounding talc-related liabilities remain a key risk factor; however, the author notes that JNJ's robust cash reserves and litigation strategies mitigate the impact on investor sentiment. These developments have kept litigation concerns manageable, reducing potential downside pressures on the stock price.
Finally, the author underscores the company's strong dividend policy and consistent free cash flow generation as central reasons for its enduring appeal to income-focused investors. This dependable income stream supports the stock's valuation even amidst broader market uncertainties.

Johnson & Johnson: Analysis of Q1 Earnings Points to Stability Amid Macro Challenges

Johnson & Johnson's Q1 earnings reveal strong revenue growth driven primarily by its pharmaceutical segment, with key products showing robust performance despite competitive pressures. The ability to sustain momentum in this sector underscores the company’s resilience and positions it as a reliable investment during potentially volatile market conditions, according to the author.
The medical devices sector demonstrated moderate growth, reflecting recovery trends in elective procedures post-pandemic. While this segment may not be JNJ's largest growth driver, its steady performance signals balanced diversification and stability in revenue streams.
Outlook for Consumer Health Division and Financial Strength
The consumer health division, while facing headwinds from inflationary pressures, continues to contribute positively due to strong brand recognition and pricing power. As observed by the author, this segment remains an asset for long-term valuation, though near-term volatility in consumer spending may cap growth expectations.
JNJ’s strong balance sheet and free cash flow generation further reinforce confidence in its ability to navigate external uncertainties, including legal liabilities and macroeconomic fluctuations. The author highlights how prudent capital allocation and dividend stability bolster JNJ’s appeal to investors seeking defensive stocks.

Johnson & Johnson: Balanced Valuation with Recession-Proof Appeal

Johnson & Johnson’s current valuation appears reasonable, supported by its diverse portfolio of consumer health products, pharmaceuticals, and medical devices. These divisions collectively provide a robust revenue base, offering stability across economic cycles. The author highlights the company's potential to outperform during economic downturns, which is particularly significant for investors seeking defensive positions amidst volatility.
Factors Affecting JNJ’s Stock Price
The strength of JNJ’s pharmaceutical pipeline, including upcoming drug launches and clinical trial results, serves as a critical growth driver. Positive developments in this area could act as catalysts for stock price appreciation in the near term. Meanwhile, litigation risks surrounding talc-related cases remain a key concern, as unfavorable outcomes might create downward pressure. Investors should monitor developments in this area closely given its potential material impact.
In addition, JNJ’s shareholder-friendly policies, including consistent dividend payments and share repurchases, underscore its commitment to delivering value. These measures enhance investor confidence and have historically supported its stock during periods of uncertainty.
Johnson & Johnson's strategic integration of Kenvue underscores its commitment to leveraging growth in the consumer health segment, where the spinoff has improved operational efficiency and focus. Array highlights that combining the predictable cash flow from Kenvue products with JNJ’s larger pharmaceutical and medical device operations creates a diversified earnings profile appealing to investors.
Key Factors Driving Potential Share Performance
The pharmaceutical portfolio remains a cornerstone, with JNJ’s efforts in expanding its pipeline and addressing patent-focused risks likely to sustain long-term growth. The author emphasizes that these initiatives can mitigate challenges stemming from biosimilar competition in key revenue-generating drugs.
Risks associated with litigation and legal liabilities, particularly those tied to talc lawsuits, continue to weigh on sentiment. However, Array notes that JNJ's robust financial position and decisive legal strategies mitigate fears of outsized impacts on financial performance.
The dividend yield, a hallmark of JNJ’s stock, is highlighted as a compelling factor for income-focused investors. This stability, coupled with ongoing share buyback programs, reinforces confidence in the stock’s attractiveness amid market volatility.
The analysis highlights Johnson & Johnson's diversified product portfolio as a key strength, showcasing resilience across pharmaceuticals, medical devices, and consumer health sectors. According to the author, these segments provide robust revenue streams and limit exposure to market-specific risks, underpinning the company’s stability in fluctuating healthcare cycles.
Regulatory and legal scrutiny remains a critical factor to monitor, as litigation risks associated with talc-related lawsuits and other issues could weigh on profitability. While the author notes that JNJ has reserved funds to address such liabilities, the potential for unexpected legal costs remains a concern for near-term stock performance.
R&D and Innovation Drive
Investment in research and development positions JNJ to compete effectively in high-growth areas such as oncology and immunology. The author emphasizes that JNJ’s continued pipeline advancements indicate potential future catalysts for revenue expansion, which may bolster investor confidence over time.
Macroeconomic headwinds, including inflationary pressures, are cited as factors that could affect operational costs. However, JNJ's scale and operational efficiency likely mitigate the impact, keeping profit margins relatively stable.
Johnson & Johnson's recent acquisition of Intra-Cellular Therapeutics is a pivotal move aligning with the company’s strategic focus on innovation within high-growth sectors. The transaction underscores JNJ's commitment to expanding its pharmaceutical pipeline, particularly in neurology and mental health, areas of increasing demand and robust growth potential.
Financially, the acquisition reflects JNJ's strong liquidity position, allowing it to pursue transformative deals without compromising its balance sheet stability. The author highlights that the deal could bolster revenues and catalyze long-term earnings growth, improving shareholder value amid an evolving competitive landscape.
Broader Sector Implications
Additionally, the expanding focus on mental health pharmaceuticals suggests JNJ is leveraging shifts in healthcare demand to maintain its leadership. This strategic pivot not only mitigates potential post-COVID headwinds in other divisions but strengthens its positioning within a market expected to grow exponentially over the next decade.
Finally, the potential for cost synergies and intellectual property gains through this acquisition may heighten operational efficiency, supporting long-term margin expansion. This positioning could provide JNJ with differential advantages as the pharmaceutical sector faces rising R&D costs and price pressures globally.
Johnson & Johnson's diversified portfolio, particularly its robust consumer healthcare and pharmaceutical segments, offers significant protection against macroeconomic headwinds. The article highlights that JNJ's strong brand presence and consistent demand for staple products provide stability in revenue streams, which is especially critical in periods of economic uncertainty.
The company's innovation pipeline is another cornerstone of its valuation, with management emphasizing upcoming launches across its pharmaceutical and MedTech divisions. According to the author, these advancements position JNJ to maintain a competitive advantage and drive long-term growth, even in an increasingly crowded healthcare market.
Dividend Stability and Shareholder Confidence
A crucial factor for investors is JNJ's impressive dividend history, underpinned by a healthy balance sheet and free cash flow generation. The author suggests that this reliability solidifies investor confidence, making it an attractive option for income-focused portfolios, particularly for those seeking defensive stocks.
The ongoing litigation risk from talc-related lawsuits remains a notable overhang but appears manageable given the company's financial reserves and legal strategy. While this issue introduces some uncertainty, the author argues it is unlikely to derail the broader growth trajectory or JNJ’s ability to meet shareholder commitments.
Johnson & Johnson's diversified business model, spanning pharmaceuticals, medical devices, and consumer health products, is a primary strength. This multi-segment structure allows the company to mitigate risks in any single market, providing a steady revenue foundation despite economic uncertainties.
Growth in the pharmaceutical segment, driven by key products like Stelara and Darzalex, remains a cornerstone of JNJ's value proposition. Robust performance in this segment, coupled with a strong pipeline of research and development initiatives, enhances its competitive positioning in high-margin areas.
Impacts of Litigation and Spin-Off Developments
The ongoing talc-related litigation poses significant financial and reputational risks for Johnson & Johnson. A resolution, whether through settlement or legal proceedings, will likely influence investor sentiment and near-term stock performance.
The recent spin-off of the consumer health segment, Kenvue, marks a strategic pivot toward higher-margin sectors. This restructuring aligns with the company's focus on pharmaceuticals and medical devices, potentially unlocking long-term shareholder value despite short-term market volatility.
The company's financial stability, underscored by its AAA credit rating, reinforces investor confidence. Consistent dividend payments and prudent capital allocation strategies further highlight JNJ's commitment to shareholder returns.
Johnson & Johnson's diversified portfolio remains a critical driver of its consistent performance, mitigating risks associated with its exposure to any single market or product line. The author emphasizes that this diversification strategy significantly insulates the company from macroeconomic volatility and contributes to its stable revenue generation.
Strong performance in J&J’s pharmaceutical segment has been highlighted, particularly its innovative drug pipeline and successful launches. These factors are bolstering growth while reinforcing the company's competitive position, signaling continued contribution to its stock's upward trajectory.
Significance of Financial Stability and Legal Developments
The company's robust balance sheet and free cash flow generation are underscored as pivotal enablers for continued shareholder returns through dividends and buybacks. Such financial stability also facilitates substantial reinvestment into R&D, sustaining long-term growth potential.
Ongoing legal headwinds, particularly related to talc litigation, pose a non-trivial risk but appear to be adequately provisioned for. While these issues may create near-term stock price volatility, the author suggests that J&J’s financial resilience limits their systemic impact on the company’s overall valuation.
Johnson & Johnson's recent Q4 performance showed a notable earnings miss, which was a focal concern for investors. The author's analysis highlights that the miss is tied to weaker-than-expected performance in certain segments of the business, particularly within pharmaceuticals and medical devices—two areas typically seen as growth drivers. This could weigh on short-term sentiment as the market digests the implications for future profitability.
One of the key points raised is the impact of macroeconomic headwinds on operational costs and revenue growth. Rising input costs and a challenging regulatory landscape appear to have affected margins, though the author suggests these are more cyclical risks than structural flaws. Such conditions could limit upside potential in the near term but may present an opportunity to accumulate shares at lower valuations if cost pressures ease.
Market Position and Long-Term Outlook
The report also underscores J&J's strong competitive barriers, backed by its diversified product portfolio and global reach. These strengths are expected to underpin long-term stability and maintain the company as a leader in healthcare, even if current performance trends remain subdued. The author notes that management's disciplined capital allocation and focus on innovation could support a recovery trajectory when macro pressures subside.
In addition, J&J's dividend remains a key attraction for income-focused investors. The solid track record of dividend growth, even during challenging quarters, signals underlying resilience and shareholder-friendly policies. This aspect could help mitigate the impact of softer earnings on investor confidence in the short term.
Johnson & Johnson's Q4 earnings performance is underscored by solid execution in its pharmaceutical division, yet the author highlights potential constraints from declining performance in consumer health. While the pharmaceutical segment continues to be a key growth driver, the weakness in consumer health reflects challenges in the broader macroeconomic environment, potentially limiting substantial near-term upside.
An ongoing liability from talc-related lawsuits poses a significant overhang on the stock. The author's analysis suggests that these legal uncertainties, combined with the associated risk of financial impairment, may dampen investor sentiment and weigh on the valuation momentum despite an otherwise stable business outlook.
Near-Term Catalysts Are Limited
The transition into a leaner business model with the planned Kenvue spin-off is another focal point, but the expected value accretion is likely to materialize over the medium to long term. The article points to a lack of immediate operational catalysts in the post-spin-off structure, which could result in stock price stagnation until clearer growth signals emerge.
Moreover, the company's forward guidance emphasizes conservative expectations, reinforcing the narrative of minimal short-term catalysts. The muted outlook, as per the author, reflects prudent management but might dampen enthusiasm for significant near-term capital appreciation.
The author highlights Johnson & Johnson's strategic acquisition of Intra-Cellular Therapies, emphasizing its potential to diversify JNJ's product portfolio, particularly in innovative neurological treatments. This acquisition positions JNJ to capture a share of the rapidly growing neurological disorder market, which could significantly enhance top-line growth in the medium to long term.
Implications of Key Market Trends
An additional focal point is the synergy between Intra-Cellular Therapies' product pipeline and JNJ's R&D prowess, hinting at enhanced drug development capabilities. If maximized, such integration could increase operational efficiency and provide a competitive edge, positively impacting margins over time.
The author also underscores the regulatory landscape as a potential risk factor, noting that delays or failures in FDA approvals could moderate short-term returns. Nevertheless, JNJ's historical success in navigating regulatory hurdles suggests that this risk may be well-managed, though it remains a point of vigilance for investors.
Comprehensive Analysis of Johnson & Johnson (JNJ) Stock Market Performance
Our multifaceted analysis of Johnson & Johnson's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Johnson & Johnson stock?
- When should I record a loss on Johnson & Johnson stock?
- What are analysts' forecasts for Johnson & Johnson stock?
- What is the future of Johnson & Johnson stock?
We forecast Johnson & Johnson stock performance using neural networks based on historical data on Johnson & Johnson stocks.
If you’re shopping around for top-notch dividend kings to invest in, consider placing Johnson & Johnson (NYSE:JNJ) at the top of your list. For over six decades, this US pharmaceutical titan has been consistently boosting its dividends and currently gifts investors with a quarterly dividend of $1.19 per share. On September 23, it recorded a pretty decent dividend yield of 2.97%.
Recent data suggests that the popularity of Johnson & Johnson (NYSE:JNJ) among hedge funds is on the rise. At the end of Q2 2023, it held a spot in the portfolios of 88 hedge funds, a slight jump from 86 during the previous quarter. What makes this even more significant is that these stakes tally up to a value north of $4.1 billion!
Johnson & Johnson manufactures hygiene products, first aid medicines and medical equipment. Compeed adhesive plasters, Johnson’s Baby care for children, Neutrogena cosmetics, Clean & Clear cleansers and Acuvue contact lenses are the company’s products.
The holding includes 250 companies with three areas of activity: pharmaceuticals, consumer goods and medical equipment manufacturing. Johnson & Johnson products are sold in 175 countries. In 2016, the company earned $ 71.9 billion.
The Johnson brothers originally produced sterile surgical dressings. The first batch went on sale in 1886. Johnson & Johnson’s dressings grew in popularity and were safe and ready to use. In 1916 Johnson & Johnson bought the first textile manufactory. By 1919, the brothers had established a subsidiary in Canada, and by 1924 in the UK. In 1927, the company produced baby cosmetics, feminine hygiene products and adhesive plasters.
Johnson & Johnson News influencing stock rates

As of now, Panda has combed through 9 news items directly related to JNJ from the last 30 days. Out of these, 5 clearly showcase a bullish trend, while 1 display bearish tendencies, and 3 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 4.75 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from Apr 15, 2025, to Apr 26, 2025.
Johnson & Johnson: MedTech's Top Bet Amid Economic Uncertainty


Johnson & Johnson's TAR-200 Data Marks Potential Breakthrough in Bladder Cancer Therapy


J&J Ends 20-Year Partnership, Returns Epilepsy Drug Rights to Addex


Johnson & Johnson Braces for $400M Tariff Blow in 2025


Johnson & Johnson Targets $92B in Sales by 2025 with MedTech Innovation


Johnson & Johnson Boosts Outlook Amid Sector Tariff Concerns


Healthcare Stocks Surge as Market Rebounds Amid Trade Tariff Optimism


J&J Secures FDA Nod for Tremfya in Crohn's Disease


Johnson & Johnson Pledges $55 Billion U.S. Investment Surge


HHS HIV Prevention Cuts Could Ripple Through Pharma Giants


Johnson & Johnson daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 01 | 155.58 | 155.26 | 156.50 | 0.80 |
May 02 | 155.99 | 155.35 | 156.49 | 0.73 |
May 03 | 154.51 | 153.66 | 155.36 | 1.11 |
May 04 | 153.36 | 152.41 | 154.21 | 1.18 |
May 05 | 153.90 | 152.95 | 154.22 | 0.83 |
May 06 | 155.21 | 154.21 | 156.01 | 1.17 |
May 07 | 155.16 | 154.49 | 156.08 | 1.02 |
May 08 | 155.74 | 155.02 | 156.22 | 0.77 |
May 09 | 156.70 | 156.23 | 157.50 | 0.81 |
May 10 | 157.09 | 155.85 | 157.60 | 1.12 |
May 11 | 157.72 | 156.85 | 158.60 | 1.12 |
May 12 | 158.84 | 158.32 | 159.49 | 0.74 |
May 13 | 159.87 | 159.55 | 160.26 | 0.44 |
May 14 | 159.17 | 158.18 | 160.01 | 1.16 |
May 15 | 159.44 | 158.28 | 160.16 | 1.19 |
May 16 | 160.75 | 159.70 | 161.74 | 1.28 |
May 17 | 161.44 | 160.24 | 162.63 | 1.49 |
May 18 | 162.68 | 161.93 | 163.74 | 1.12 |
May 19 | 161.40 | 160.96 | 162.14 | 0.73 |
May 20 | 161.06 | 160.72 | 162.19 | 0.91 |
May 21 | 161.67 | 161.18 | 162.75 | 0.97 |
May 22 | 162.20 | 160.97 | 162.95 | 1.23 |
May 23 | 163.50 | 162.57 | 163.98 | 0.86 |
May 24 | 165.04 | 164.39 | 165.75 | 0.82 |
May 25 | 166.06 | 165.45 | 166.61 | 0.70 |
May 26 | 166.08 | 165.53 | 167.22 | 1.02 |
May 27 | 165.20 | 164.74 | 165.96 | 0.74 |
May 28 | 163.56 | 162.91 | 164.84 | 1.18 |
May 29 | 164.12 | 163.66 | 165.04 | 0.84 |
May 30 | 164.00 | 162.82 | 164.38 | 0.96 |
Johnson & Johnson Daily Price Targets
Johnson & Johnson Stock Forecast 05-01-2025.
Forecast target price for 05-01-2025: $155.58.
Positive dynamics for Johnson & Johnson shares will prevail with possible volatility of 0.796%.
Pessimistic target level: 155.26
Optimistic target level: 156.50
Johnson & Johnson Stock Forecast 05-02-2025.
Forecast target price for 05-02-2025: $155.99.
Positive dynamics for Johnson & Johnson shares will prevail with possible volatility of 0.728%.
Pessimistic target level: 155.35
Optimistic target level: 156.49
Johnson & Johnson Stock Forecast 05-03-2025.
Forecast target price for 05-03-2025: $154.51.
Negative dynamics for Johnson & Johnson shares will prevail with possible volatility of 1.094%.
Pessimistic target level: 153.66
Optimistic target level: 155.36
Johnson & Johnson Stock Forecast 05-04-2025.
Forecast target price for 05-04-2025: $153.36.
Negative dynamics for Johnson & Johnson shares will prevail with possible volatility of 1.164%.
Pessimistic target level: 152.41
Optimistic target level: 154.21
Johnson & Johnson Stock Forecast 05-05-2025.
Forecast target price for 05-05-2025: $153.90.
Positive dynamics for Johnson & Johnson shares will prevail with possible volatility of 0.828%.
Pessimistic target level: 152.95
Optimistic target level: 154.22
Johnson & Johnson Stock Forecast 05-06-2025.
Forecast target price for 05-06-2025: $155.21.
Positive dynamics for Johnson & Johnson shares will prevail with possible volatility of 1.154%.
Pessimistic target level: 154.21
Optimistic target level: 156.01
JNJ (JNJ) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May. | 156.11 | 153.68 | 158.31 | 2.93 |
Jun. | 157.05 | 153.33 | 160.68 | 4.57 |
Jul. | 158.65 | 157.70 | 161.31 | 2.24 |
Aug. | 154.75 | 153.82 | 157.49 | 2.33 |
Sep. | 155.68 | 152.36 | 159.22 | 4.31 |
Oct. | 153.48 | 152.05 | 155.69 | 2.34 |
Nov. | 153.43 | 151.78 | 157.02 | 3.34 |
Dec. | 155.55 | 153.68 | 156.67 | 1.91 |
Johnson & Johnson forecast for this year
Johnson & Johnson Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $156.11. Pessimistic: $153.68. Optimistic: $158.31
Johnson & Johnson Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $157.047. Pessimistic: $153.33. Optimistic: $160.68
Johnson & Johnson Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $158.649. Pessimistic: $157.70. Optimistic: $161.31
Johnson & Johnson Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $154.746. Pessimistic: $153.82. Optimistic: $157.49
Johnson & Johnson Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $155.675. Pessimistic: $152.36. Optimistic: $159.22
Johnson & Johnson Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $153.48. Pessimistic: $152.05. Optimistic: $155.69
Johnson & Johnson Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $153.434. Pessimistic: $151.78. Optimistic: $157.02
Johnson & Johnson Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $155.551. Pessimistic: $153.68. Optimistic: $156.67
Johnson & Johnson (JNJ) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 154.66 | 152.62 | 157.12 | 2.86 |
Feb | 157.45 | 154.19 | 160.42 | 3.89 |
Mar | 158.63 | 155.06 | 160.72 | 3.52 |
Apr | 154.73 | 153.10 | 156.35 | 2.08 |
May | 159.09 | 155.27 | 162.29 | 4.32 |
Jun | 162.24 | 159.86 | 165.50 | 3.41 |
Jul | 165.84 | 164.45 | 169.37 | 2.91 |
Aug | 168.88 | 167.05 | 171.51 | 2.60 |
Sep | 169.84 | 166.43 | 173.41 | 4.03 |
Oct | 172.74 | 170.05 | 176.63 | 3.73 |
Nov | 173.68 | 172.11 | 177.32 | 2.94 |
Dec | 170.08 | 166.10 | 171.61 | 3.21 |
Johnson & Johnson (JNJ) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 165.23 | 163.70 | 168.41 | 2.80 |
Feb | 165.58 | 161.91 | 166.92 | 3.01 |
Mar | 161.26 | 157.92 | 162.61 | 2.89 |
Apr | 163.00 | 160.12 | 165.50 | 3.25 |
May | 163.15 | 159.67 | 165.64 | 3.60 |
Jun | 164.67 | 161.06 | 166.54 | 3.29 |
Jul | 166.49 | 162.65 | 169.59 | 4.09 |
Aug | 166.99 | 164.94 | 170.30 | 3.15 |
Sep | 162.58 | 159.27 | 165.61 | 3.83 |
Oct | 159.22 | 155.97 | 161.51 | 3.43 |
Nov | 155.83 | 152.51 | 157.46 | 3.15 |
Dec | 153.86 | 150.45 | 156.36 | 3.78 |
Johnson & Johnson information and performance
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, US
Market capitalization of the Johnson & Johnson is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of JNJ shares in the company outstanding by the market price of one share.
EBITDA of Johnson & Johnson is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Johnson & Johnson (JNJ) stock dividend
Johnson & Johnson last paid dividends on 05/27/2025. The next scheduled payment will be on 06/10/2025. The amount of dividends is $4.96 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Johnson & Johnson Stock)
Should I Buy Johnson & Johnson Shares in 2025 year?
Does Johnson & Johnson pay dividends?
Which economic sector do Johnson & Johnson's shares belong to?
Which other securities belong to the same sector as Johnson & Johnson's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.